CDISC SDTM Normal Abnormal Response Terminology CDISC SDTM Protocol Risk Assessment Response Codelist CDISC SDTM Coronary Vessel Disease Extent Terminology CDISC SDTM Cardiac Procedure Indication Terminology International Neuroblastoma Pathology Classification Reason Treatment Not Administered Pretreatment WEISS System WEISS Criteria Pathologic ENSAT Staging Finding v7 Pathologic Primary Tumor ENSAT Staging Finding v7 Pathologic Lymph Nodes ENSAT Staging Finding v7 Clinical Distant Metastasis ENSAT Staging Finding v7 ECOG Performance Status Tumor Regression Grade Mitosis-Karyorrhexis Index Menopause Status Number of Pregnancies Testicular Cancer Serum Markers Test Result International Germ Cell Consensus Risk Classification Premature Birth Indicator CNS Involvement Status at Leukemia Diagnosis Tumor Identifier Method Procedure Laterality Tumor Findings Laterality Tumor Findings Specimen Type Child-Pugh Clinical Classification Surgical Margins Status CDISC SDTM Tumor and Lesion Identification Test Result Terminology CDISC SDTM Subject Status Response Terminology CDISC SDTM Treatment Intent Terminology CDISC SDTM Treatment Setting Terminology FIGO Stage High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements Tumor Response System Drinking Status CDISC SDTM Mode of Disease Transmission Terminology Staining Intensity Perineural Invasion Assessment Vascular Invasion Assessment CDISC SDTM Collected Race Terminology CDISC SDTM Collected Ethnicity Terminology Malignant Cell Medulloblastoma Molecular Subtypes Chromosome CDISC Protocol Terminology Protocol Identifier International Neuroblastoma Risk Group Staging System Chromosome Arm Mismatch Repair Gene Mutation Radiation Boost Double-Expressor Lymphoma International Staging System Stage Enneking Staging System Enneking Surgical Grade Enneking Tumor Type Enneking Metastasis Concurrent Chemoradiation International Society of Urological Pathology Gleason Grade Group Masaoka-Koga Stage CDISC SEND Null Flavor Reason Terminology Amputation Biopsy Procedure Hysterectomy Radiation Therapy Total-Body Irradiation Ulcer Indicator Hormone Replacement Therapy Site of Resection or Biopsy Tissue or Organ of Origin Select Exposure Types Specify HPV Genotype Site of Tumor What is the First Presenting Symptom Related to Disease Question What is the Hormonal Contraceptive Use Status Question Tumor Focality Eye Color Extent of Resection GDC Terminology CDISC SEND Age Estimation Method Response Terminology Primary Site of Disease Specify Molecular Abnormality Analysis Method WHO AML Classification of Tumors Cytogenetic Risk Group-CALGB Criteria for AML Was Lymph Node Dissection Performed Question Is Individual Lost to Follow-Up Question Limb Salvage Procedure Is Lymphatic Invasion Present Question Is Macroscopic Satellite Nodule Present Question Is Extranodal Tumor Involvement Present Question Transglottic Extension of Laryngeal Tumor Prior Therapy Comorbid Condition Surgical Procedure by Type Highly Active Antiretroviral Therapy Metastatic Diagnosis Smoke Exposure Surgical Site Comorbidity Adverse Event Treatment Emergent Indicator Restriction Endonuclease ICDC Terminology Ethnic Group CDISC SDTM Severity Response Terminology Agent Unit of Measure Adverse Event Severity Grade Normal or Tumor Sample Pathology Indicator Reason Off Treatment Histology Histone PQ/CMC Organization-Site Identifier Type Terminology Pathogenicity Extramedullary Myeloid Sarcoma Site GVHD Acuity Type of Stem Cell Transplant Cause of Death Detail Stem Cell Transplant Donor Relationship Stem Cell Transplant Source Karyotype Status Adverse Event Grading System Disease Phase Traumatic Tap GVHD Organ Measurable Residual Disease Molecular Marker HLA-A Match Finding HLA-B Match Finding HLA-C Match Finding HLA-DRB1 Match Finding HLA-DQ Match Finding Cause of Death Ranking Pathogen Confirmation Indicator Measurable Residual Disease Sample Source BM Analysis Modality at Response ANC Threshold at Response Platelet Threshold At Response Neoplasm Stage HLA Match Finding Type of Stem Cell Transplant Conditioning Prior to Transplant Question Ploidy Race Risk Factor Fusion Gene Downstream Gene Symbol Passive Smoke Exposure Specimen Anatomic Site Site of Metastasis Transfusion Type CTDC Value Terminology AML Off Protocol Therapy/Study Table AML Medical History Table AML Myeloid Sarcoma Involvement Table AML Lab Table AML Subject Response Table AML Vitals Table AML Adverse Events Table AML Demographics Table AML Survival Characteristics Table AML Disease Characteristics Table AML Molecular Analysis Table AML Total Dose Table AML Stem Cell Transplant Table AML Minimal Residual Disease Table AML Function Test Table AML Cellular Immunotherapy Table AML Concomitant Medication Table AML Radiation Therapy Table AML Transfusion Medicine Procedures Table Treatment-related Mortality Type Disease Involvement Detection Method Disease Involvement Site Lab Result Unit Site of Radiation Therapy Transfusion Product Type of Cellular Immunotherapy Total Dose Units Medication Administration Status Number of Matched HLAs Measurable Residual Disease Unit Response Assessment Category Echocardiogram Result Unit Intensive Care Unit Admission Status Adverse Event Medication Adverse Event Intervention Intervention/Medication Detail Off Protocol Therapy or Study Reason Code Molecular Sequence Variation Type Gender First Variant Gene Symbol Molecular Abnormality Result Indicator Imaging Procedure Flow Cytometry Type AML Authorized Value Terminology EWS Authorized Value Terminology EWS Adverse Events Table EWS Biopsy/Surgical Procedures Table EWS Demographics Table EWS Disease Characteristics Table EWS Histology Table EWS Lab Table EWS Molecular Analysis Table EWS Non-Protocol Therapy Table EWS Radiation Therapy Table EWS Secondary Malignant Neoplasm Table EWS Stem Cell Transplant Table EWS Subject Response Table EWS Survival Characteristics Table EWS Tumor Assessment Table EWS Vitals Table GPOH Performance Status Joint Involvement Skip Lesion Ipsilateral Nodule Tumor Classification Site within Bone Pleural Cytology Limb Surgery Surgical Management of Metastatic Non-Lung Disease Surgical Management of Metastatic Lung Disease Organ Transposition Procedure Non-Protocol Therapy Timing Non-Protocol Therapy Type Location of Second Malignant Neoplasm related to Prior Radiation Field ICDC Value Terminology Radiation Therapy Laterality Peritoneal Cytology Information Source for Cause of Death Imaging Finding Histology ICD-O Morphology Code Malignant Germ Cell International Collaborative Risk Classification Nodal Site Source of Institutional or Central Histological Assessment Numeric Histology Result Unit Mature Glial Implant Somatic-Type Malignancy Growing Teratoma Syndrome Treatment Patient Reported Outcome Measures GCT Authorized Value Terminology GCT Demographics Table GCT Medical History Table GCT Survival Characteristics Table GCT Disease Characteristics Table GCT Tumor Assessment Table GCT Staging Table GCT Histology Table GCT Vitals Table GCT Lab Table GCT Cytology Table GCT Molecular Analysis Table GCT Biopsy/Surgical Procedures Table GCT Radiation Therapy Table GCT Total Dose Table GCT Subject Response Table GCT Adverse Events Table GCT Growing Teratoma Syndrome Table GCT Patient Reported Outcomes Metadata Table Cytology Specimen Type GDC Value Terminology IRS Clinical Grouping System IRS Clinical Staging System AJCC v8 Clinical Stage AJCC v8 Pathologic Stage Molecular Test Analyte Type Ann Arbor Clinical Stage Ann Arbor Pathologic Stage AJCC Cancer Staging Manual European LeukemiaNet Risk Classification Comorbidity Diagnostic Method International Neuroblastoma Pathology Classification Histologic Group WHO Central Nervous System Grade WHO Neuroendocrine Tumor Grade Wilms Tumor Histologic Subtype Anatomic Site for Involved Surgical Margin Progressive or Recurrent Disease Anatomic Site Supratentorial Tumor Site Normal and Tumor Sample Distance Diagnostic Method Disease Recurrence Evidence Dysplasia Degree Question Country of Residence at Enrollment Target Capture Kit Identifier Ann Arbor B Symptoms Indicator Ann Arbor Extranodal Involvement Indicator Bone Marrow Malignant Cell Indicator Burkitt Lymphoma Clinical Variant Indicator Columnar Mucosa Indicator Diagnosis Pathologically Confirmed Indicator Esophageal Columnar Metaplasia Indicator Gastroesophageal Junction Involvement Indicator Esophageal Columnar Mucosa Goblet Cell Indicator Hysterectomy Margins Involved Indicator Metaplasia Indicator Necrosis Indicator Non-nodal Regional Disease Indicator Non-nodal Tumor Deposits Indicator Genotype Match Indicator for Normal/Tumor Matched Tissue Samples Ovarian Surface Involvement Indicator Progressive or Recurrent Disease Indicator Rhabdoid Indicator Risk Factor Treatment Indicator Genetic Variant Origin Indicator Biospecimen Laterality AJCC v8 Clinical M Category AJCC v8 Pathologic M Category Ovarian Capsule Status Hepatitis Serology Instrument Model AJCC v8 Clinical N Category AJCC v8 Pathologic N Category ChIP-Seq Antibody Name ChIP-Seq Target Name Initial Neoplastic Disease Extent Indicator Pregnant at Diagnosis Indicator Histone Variant ICD-O-3 Morphology Term Diagnosis Question Family Cancer History Relative Sex Question Risk Factors for HIV Infection Secondhand Smoke Exposure as a Child Question Current Smoking Frequency Question Time Between Waking and First Smoke Question Children's Oncology Group Liver Tumor Staging System Children's Oncology Group Neuroblastoma Risk Group Staging System Children's Oncology Group Renal Cancer Staging System Children's Oncology Group Retinoblastoma Risk Group Staging System Hepatitis Sustained Virologic Response AJCC v8 Clinical T Category AJCC v8 Pathologic T Category Reflux Treatment Type Indicator Therapeutic Effect Indicator Progression or Recurrence Type Esophageal Columnar Dysplasia Degree Question Enrolled in Another Therapeutic Study After Off Study Last Known Survival Status with Disease Bulky Mediastinal Mass Subject Received Steroids Within One Week Prior to Diagnosis of Disease Phase Subject Received Steroids Within One Month Prior to Diagnosis of Disease Phase Avascular Necrosis of the Joint ALL Off Protocol Therapy/Study Table ALL Medical History Table ALL Lab Table ALL Radiation Therapy Table ALL Stem Cell Transplant Table ALL Authorized Value Terminology ALL Survival Characteristics Table ALL Demographics Table ALL Disease Characteristics Table ALL Vitals Table ALL Molecular Analysis Table ALL Minimal Residual Disease Table ALL Adverse Events Table Response Assessment Method Family Cancer History Relative Primary Diagnosis Question Number of Peripancreatic Lymph Nodes Positive Anaplasia Indicator Anaplasia Descriptor Vascular Invasion Descriptor Largest Diameter of Extrapelvic Peritoneal Metastasis SeroNet Research Participant Metadata SeroNet Prior Test Result SeroNet Authorized Values OS Authorized Value Terminology OS Subject Response Table OS Tumor Assessment Table OS Biopsy/Surgical Procedures Table OS Radiation Therapy Table OS Subject Characteristics Table OS Patient Reported Outcomes Metadata Table OS Histology Table OS Medical History Table OS Lab Table OS Adverse Event Table OS Survival Characteristics Table Education Level OS Total Dose Table OS Vitals Table OS Demographics Table OS Molecular Analysis Table Unknown CTDC Unknown Idea or Concept Unknown C17998 Not known, not observed, not recorded, or refused. (NCI) Unknown/Not Stated C0439673 Not known, not observed, not recorded, or refused. GDC Not known, observed, recorded; or reported as unknown by the data contributor. DIPG/DMG Nonspecific unknown OORO UNK SeroNet UNKNOWN Not Known {Unknown} U Reported as unknown by the data contributor. A proper value is applicable but not known. ICDC FDA ACC/AHA Unknown PCDC Unknown Used for Cancer Activities Coding when cancer activity is not specified. CDISC Histologic Grade Staging System Radiation Dose Unit Consistent Pathology Review Indicator Corrected Undescended Testis Laterality Parent with Radiation Exposure Indicator Undescended Testis Corrected Indicator Undescended Testis History Indicator Undescended Testis Corrected Method Undescended Testis Laterality Adrenal Hormone Indicator Image Anatomic Location Clonality CRF1 Registration Table CRF2 History and Physical Exam at Diagnosis Table CRF2 History and Physical Exam Family Medical History Table CRF2 History and Physical Exam Patient Medical History Table CRF3 Diagnosis Biopsy Table CRF3 Diagnosis CSF Table CRF3 Diagnosis CT Scan Table CRF3 Diagnosis Hydrocephalus Table CRF3 Diagnosis MR Spectroscopy Table CRF3 Diagnosis MRI Brain Table CRF3 Diagnosis MRI Spine Table CRF3 Diagnosis PET Imaging Table CRF3 Diagnosis Re-Biopsy Table CRF3 Diagnosis Table CRF4 Treatment Additional Surgeries Table CRF4 Treatment Chemotherapy Table CRF4 Treatment Complementary Table CRF4 Treatment Re-Irradiation Table CRF4 Treatment Radiation Table CRF4 Treatment Steroids during Re-Irradiation Table CRF4 Treatment Steroids during Radiation Table CRF4 Treatment Steroids Table CRF4 Treatment Surgery Table CRF4 Treatment Table CRF5 Response Evaluation Clinical Evaluation Table CRF5 Response Evaluation Image Evaluation Table CRF5 Response Evaluation Time Point Table CRF6 DIPG Imaging Assessment Table CRF6 DMG Imaging Assessment Table CRF7 Pathology Review Table CRF8 Pathology Review Targeted Genomics Table Personal History Neoplasm Type Question Extraocular Nodule Size Read Group Adapter Content Quality Control Indicator Read Group Basic Statistics Quality Control Indicator Read Group Kmer Content Quality Control Indicator Read Group Overrepresented Sequences Quality Control Indicator Read Group Per Base N Content Quality Control Indicator Read Group Per Base Sequence Content Quality Control Indicator Read Group Per Base Sequence Quality Indicator Read Group Per Sequence G/C Content Quality Control Indicator Read Group Per Sequence Quality Score Indicator Read Group Per Tile Sequence Quality Indicator Read Group Sequence Duplication Levels Quality Control Indicator Read Group Sequence Length Distribution Quality Control Indicator Adverse Event Pathogen HL Demographics Table HL Family Medical History Table HL Medical History Table HL Survival Characteristics Table HL Staging Table HL Lesion Characteristics Table HL Biopsy/Surgical Procedures Table HL Lab Table HL Protocol Treatment Modifications Table HL Radiation Therapy Table HL Adverse Events Table HL Secondary Malignant Neoplasm Table HL Patient Reported Outcomes Metadata Table HL Authorized Value Terminology Personal Medical History How Often Have Alcoholic Drink Question Exposure Source Indicator Asbestos Exposure Mineral Type Indicator Therapeutic Agent Category UICC Clinical M Category UICC Clinical N Category UICC Clinical Stage UICC Clinical T Category UICC Pathologic M Category UICC Pathologic N Category UICC Pathologic Stage UICC Pathologic T Category Individual Cancer History SeroNet Study Descriptors Outcome of Therapy Pharmacologic Substance ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology Appendix 3: COVID-19 Diagnosis Terminology Appendix 4: COVID-19 Cardiovascular Complications Terminology Appendix 5: COVID-19 Noncardiovascular Complications Terminology Appendix 6: Symptoms and Signs Terminology Appendix 7: Diagnostic Procedures Terminology Appendix 8: Pharmacological Therapy Terminology Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology Appendix 10: End-of-Life Management Terminology Acute Cardiovascular Complications Related to COVID-19 Infection Terminology Cardiovascular Mortality During Acute COVID-19 Infection Terminology Current Symptoms and Signs: Clinical Symptoms Terminology Electrophysiological Procedures Terminology Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology Mechanical Support Terminology Physical Examination Terminology Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19 Terminology Therapies for COVID-19 Terminology Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission) Terminology Therapies for Supportive Care During COVID-19 Infection Terminology ACC/AHA COVID-19 Appendix Authorized Values Operational Ontology for Radiation Oncology Prostate Cancer Terminology Preservation Procedure Tissue Sample National Health Interview Survey Molecular Analysis Smoking Status Cancer Detection Method Chemical Exposure Type Indicator Disease Progression Evidence Extracapsular Extent Indicator First Post-treatment Event Lymph Node Dissection Site Variant Codon Position Number Peritoneal Wash Cytology Results Indicator Residual Tumor Size Measurement Risk Factor Diagnostic Method Therapeutic Agent Level Achieved Indicator Test Value Percent Range Therapeutic Agent Targeted Administration Concentration Timepoint Event Category Tumor Grade Evaluation Tier Number UICC Staging System Manual Clinical Finding Detected by Imaging Birth Country Anatomic Site or Organ with Contiguous Invasion Tumor Measurement Method Melanoma with Known Primary Indicator Family History of Smoking Whole Genome Sequencing Read Depth Tumor Depth Descriptor Tumor Shape Observed Descriptor Tumor Infiltrating Lymphocytes Finding Indicator Tumor Infiltrating Macrophages Finding Indicator International Prognostic Index Extracapsular Extension Present Indicator Extrathyroid Extent Indicator Histological Progression Type Micrometastasis Present Indicator Non-Oncologic Therapeutic Agent Therapeutic Oxygen Use Indicator Home Oxygen Therapy Use Duration Indicator Radiosensitizing Agent Used Indicator Number of Values in Staining Intensity Scale CDISC SDTM Action Taken with Tobacco Product Terminology Prescribed Dose Units Hormone Replacement Therapy Status Indicator Papillary Renal Cell Carcinoma Type Indicator CDISC SDTM Intersex Diagnosis Indicator Response Terminology CDISC SDTM Gender Identity Response Terminology CDISC SDTM Sexual Orientation Response Terminology Histological Progression Indicator Undescended Testis Corrected Age Range Epithelioid Cell Percent Range Extrascleral Extension Present Indicator Intratubular Germ Cell Neoplasia Present Indicator Spindle Cell Percent Range CDISC SDTM Microbiology Susceptibility Test Standard Character Result Terminology CDISC SDTM Clinical Status of Disease Response Terminology Tracer Laterality Marital Status Occupation Clinical Intervention or Procedure Laboratory Procedure Reconstructive Surgery Vital Status Secondary Acute Myeloid Leukemia Antigen Antineoplastic Agent General Qualifier Karnofsky Performance Status Disease Grade Qualifier Localization Sex Aneuploidy Peritoneal Effusion Family Cancer History Disease or Disorder Fracture Acute Lymphoblastic Leukemia Lymph Node by Anatomic Site Pleural Effusion Chromosomal Translocation Myeloid Sarcoma Lymph Node Involvement Morphologic Architectural Pattern Localized Neoplasm Laboratory Test Result Regional Lymph Node Involvement Therapeutic Effect Route of Administration Lansky Play-Performance Status Molecular Abnormality Sarcomatoid Features Dysplasia Surgical Margin Adverse Event Adverse Event Attribution to Product or Procedure Unit of Length Myeloid Leukemia Associated with Down Syndrome B-Symptoms Zygosity Alcoholic Beverage Residual Disease Primary Gleason Pattern Secondary Gleason Pattern Tertiary Gleason Pattern Therapeutic Procedure Adverse Event Outcome Units for Vital Signs Results Disease Response Adverse Event Attribution Category Preexisting Condition Intent To Treat FDA Individual Case Safety Report Terminology Adverse Event Outcome ICSR Terminology Operator of Medical Device ICSR Terminology Occupation ICSR Terminology Report Source ICSR Terminology Location of Event Occurrence ICSR Terminology Device Usage ICSR Terminology Immunosuppressant Clinical Data Interchange Standards Consortium Terminology Gonadal Dysgenesis Chromosomal Translocation Analysis CDISC SDTM Relation to Reference Period Terminology CDISC SDTM Sex of Individual Terminology CDISC SDTM Yes No Unknown or Not Applicable Response Terminology CDISC SDTM Action Taken with Study Treatment Terminology CDISC SDTM Adverse Event Outcome Terminology CDISC SDTM Ethnic Group Terminology CDISC SDTM Terminology Unit for Functional Test Results Biospecimen Collection Method Biospecimen Type Targeted Anatomic Site Concomitant Agent CDISC SDTM Frequency Terminology Dosage Form Unit CDISC SDTM Race Terminology CDISC SEND Terminology CDISC CDASH Terminology CDISC CDASH Concomitant Medication Dosing Frequency per Interval Terminology CDISC CDASH Exposure Dosing Frequency per Interval Terminology Deceased Family Member Alcohol Use History Cause of Death Mixed Phenotype Acute Leukemia Transient Abnormal Myelopoiesis Associated with Down Syndrome Laboratory Test Category Exposure Duration Laboratory Test Method Laboratory Specimen Type Relationship Type International Neuroblastoma Staging System Observation ICSR Terminology Dose Frequency Pregnancy Outcome French-American-British Classification Hormonal Contraception Performed Procedure Off Study Reason Code Adverse Event Grade Code Tumor Volume Best Overall Response Clark Level Finding Ishak Score Embolic Agent Molecular Sequence Variation Diabetes Therapy